NCT04611867Recruiting
Study of PRO in Patients With Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)
Study of Supportive Application With Integrated Patient-Reported Outcomes in Patients With Advanced Pancreatic or BiliaryTract Cancer (BetterEveryDay)
Source: ClinicalTrials.gov · Last updated 2 Sept 2026
Brief summary (registry, in English)
Pancreatic and biliary tract cancer are ones of the leading causes of cancer-related deaths. During the course of illness, these patients often experience marked physical suffering, psychological distress and frequent unplanned resource-demanding hospitalized care. Patients with pancreatic and lung cancer have highest rates of unplanned hospitalizations. Investigator initiated prospective "Study of Supportive Application with Integrated Patient-Reported Outcomes in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)" is to be initiated based on the great need for optimizing treatment care, reducing hospitalizations and improving outcomes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 274 (estimated)
- First submitted
- 30 Oct 2020
- Start date
- 17 Aug 2021
- Primary completion date
- 1 Aug 2027
- Lead sponsor
- Inna Chen, MD
- NCT number
- NCT04611867
What you commit to
- Study type: Interventional
- Planned participants: 274
- From 17 Aug 2021 to the primary completion date, 1 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any medical condition that the Investigator considers significant to compromise the safety of the patient or that impairs the interpretation of study assessments
Other
- No mobile device
- Exhibiting signs of overt psychopathology or cognitive dysfunction
- Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention. Participation in protocols related only to treatment will not preclude participation in the present study. Cases of doubt will be settled by the protocol responsible.
Who the study is looking for
- Adult (aged 18 and over)
- Confirmed by cytology or histology advanced lung (NSCLC) or pancreatic cancer
- Written informed consent before any study procedures
- Planning to receive 1st line systemic anticancer therapy within ≤2 weeks
- Performance status: ECOG 0-2
- Access to the internet
- Ability to read and respond to questions or able to complete questions with minimal assistance required from an interpreter or family member
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Herlev & Gentofte University Hospital, Denmark Coordinator of this site? Confirm its status | Herlev | Denmark | Recruiting |
Related publications
- What matters most early in the cancer trajectory: patient concerns and priorities in pancreatic and lung cancer (BetterEveryDay trial).Eur J Oncol Nurs · 2026 · PMID 42617508
This page is information, not medical advice. Discuss any trial with your doctor.